EXOZYMES INC.

EXOZ ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2023
Revenue $70.1K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $527.5K
SG&A Expense $1.3M
Operating Income $-1.8M
Operating Margin -2,563.5%
Interest Expense
Pretax Income $-2.0M
Income Tax Expense $42.3K
Net Income $-2.0M
Net Margin -2,909.1%
EPS (Basic) $-0.33
EPS (Diluted) $-0.33
Shares Outstanding (Basic) 6.3M
Shares Outstanding (Diluted) 6.3M
Dividends Per Share